The importance of early diagnosis and treatment in peripheral arterial disease: Insights from the PARTNERS and REACH registries

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 293-300

  Mukherjee, Debabrata ^a   Eagle, Kim ^b  

^a USA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Ankle brachial index; Atherosclerosis; Cardiovascular disease; Peripheral arterial disease; Secondary prevention

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; ACETYLSALICYLIC ACID; AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE REGISTRY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DYSLIPIDEMIA; EARLY DIAGNOSIS; FOOT CARE; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYGIENE; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; NICOTINE REPLACEMENT THERAPY; PAD AWARENESS, RISK AND TREATMENT: NEW RESOURCES FOR SURVIVAL REGISTRY; QUALITY OF LIFE; REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH REGISTRY; RESTENOSIS; SMOKING; SMOKING CESSATION PROGRAM; STROKE;

EARLY DIAGNOSIS; HUMANS; PERIPHERAL ARTERIAL DISEASE; REGISTRIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952922177     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112304     Document Type: Article

References (63)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
2. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation 2006; 114: 688-99.
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guide-lines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47: 1239-312.
4. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
5. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113: 2623-9.
6. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J Thromb Haemost 2006; 4: 2599-606.
7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
8. Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg 1999; 12: 118-22.
9. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007; 58: 309-15.
10. Rother J, Alberts MJ, Touze E, et al. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25: 366-74.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
12. Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new resources for survival--the USA PARTNERS program. Vasc Med 2001; 6: 9-12.
13. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
14. Regensteiner JG, Hiatt WR, Coll JR, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008; 13: 15-24.
15. Mohler ER III, Treat-Jacobson D, Reilly MP, et al. Utility and barriers to performance of the ankle brachial index in primary care practice. Vasc Med 2004; 9: 253-60.
16. th Annual Scientific Session of the American College of Cardiology. Orlando, FL, March 6-9, 2005.
17. Cacoub PP, Abola MTB, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Athesclerosis 2009; 204: e86-92.
18. Meadows TA, Bhatt DL, Hirsch AT, et al. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US out-patients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) Registry. Am Heart J 2009; 158: 1038-45.
19. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-206.
20. Rother J, Mas JL, Touze E, et al. Two-year cardiovascular event rates of the cerebrovascular disease subpopulation within the REduction of Atherothrombosis for Continued Health (REACH) Registry. XVII European Stroke Conference, Nice, France, May 13-16, 2008.
21. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005; 45: 456-64.
22. Blacher J, Cacoub P, Luizy F, et al. Peripheral arterial disease vs. other localizations of vascular disease: the ATTEST study. J Vasc Surg 2006; 44: 314-8.
23. Daskalopoulou SS, Pathmarajah M, Kakkos SK, et al. Associations between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 2008; 72: 441-8.
24. Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam AM, Jr. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 2007; 21: 163-6.
25. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975-80.
26. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221: 253-60.
27. Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007; (4): CD002128.
28. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs. low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 285-93.
29. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2: 243-51.
30. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42: 67-74.
31. Cui R, Iso H, Yamagishi K, et al. Relationship of smoking and smoking cessation with ankle-to-arm blood pressure index in elderly Japanese men. Eur J Cardiovasc Prev Rehabil 2006; 13: 243-8.
32. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res 2007; 38: 479-88.
33. Samson RH. The role of statin drugs in the management of the peripheral vascular patient. Vasc Endovasc Surg 2008; 42: 352-66.
34. Hackam DG, Sutan NM, Criqui MH. Vascular protection in peripheral artery disease: systematic review and modeling study. Heart 2009; 95: 1098-102.
35. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
37. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients under-going non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006; 32: 286-93.
38. Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104: 264-8.
39. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.
40. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001; 87: 1284-6.
41. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004; 15: 117-25.
42. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
44. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trial. JAMA 2009; 301: 1909-19.
45. Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277-81.
46. Wong S, Morel-Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 2006; 95: 1042-3.
47. Linnemann B, Prochow S, Mani H, Schwonberg J, Lindhoff-Last E. Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol 2009; 88: 979-88.
48. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
49. Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost 2005; 3: 2649-55.
50. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
51. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201.
52. Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004; 10: 9-18.
53. Dormandy J, Belch J on behalf of the CASPAR investigators. Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomized placebo controlled study. Vascular Annual Meeting, Baltimore, MD, June 6-10, 2007.
54. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; (1): CD003748.
55. Iida O, Nanto S, Uematsu M, et al. Cilostazol reduced target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 2005; 69: 1256-9.
56. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48: 144-9.
57. Soga R, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53: 48-53.
58. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
59. Mukherjee D, Eagle KA, Kline-Rogers E, et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol 2007; 100: 1-6.
60. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
61. Beckman JA, Higgins CO, Gerhard-Herman M. Automated oscillometric determination of the ankle-brachial index provides accuracy necessary for office practice. Hypertension 2006; 47: 35-8.
62. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
63. Kikano GE, Brown MT. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. Mayo Clin Proc 2007; 82: 583-93.